SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses
If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317.
Why Was Sarepta Sued for Securities Fraud?
Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks.
In truth, Elevidys causes fatal acute liver failure in some patients.
The Stock Declines as the Truth Is Revealed
On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.'
Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025.
Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025.
Click here for more information: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
What Can You Do?
If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action
Or contact:
Ross Shikowitz
[email protected]
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action
Attorney advertising. Past results do not guarantee future outcomes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
an hour ago
- Wall Street Journal
Soho House Members' Club Nearing a Deal to Go Private
A group of investors led by one of the country's biggest hotel owners is nearing a deal to take Soho House private, ending a monthslong contest over the fate of the giant members' club operator. Billionaire Ron Burkle, currently the controlling shareholder, is expected to roll over his stake, according to people familiar with the matter, along with several other existing shareholders. The new equity investors will be led by New York-based MCR Hotels, the people said.
Yahoo
4 hours ago
- Yahoo
Qualys (QLYS) Wins Two Pwnie Awards at DEF CON for Groundbreaking OpenSSH Vulnerability Research
Qualys, Inc. (NASDAQ:QLYS) is one of the Qualys, Inc. (NASDAQ:QLYS) is one of the best midcap AI stocks to buy right now. On August 12, 2025, Qualys announced that its Threat Research Unit (TRU) received two Pwnie Awards at the DEF CON cybersecurity conference for its groundbreaking work uncovering critical OpenSSH vulnerabilities. The awards, 'Epic Achievement' and 'Best Remote Code Execution (RCE)', recognized Qualys for identifying CVE-2024-6387, the first pre-authentication RCE in OpenSSH in nearly two decades, and CVE-2025-26465, a man-in-the-middle attack affecting FreeBSD clients. The wins cement Qualys' status as a major player in vulnerability research. welcomia/ Alongside its ongoing threat research, Qualys expanded coverage within its Enterprise TruRisk Platform on August 12, 2025, issuing new vulnerability checks tied to Microsoft's latest Patch Tuesday update. While the company did not publish a formal press release, its research portal listed 98 vulnerabilities across 12 Microsoft security bulletins, with immediate support deployed for customer environments. The update underscores Qualys' operational emphasis on rapid detection and remediation, reinforcing its reputation for delivering same-day protections aligned with major vendor disclosures. Qualys is a U.S.-based provider of cloud-native IT, security, and compliance solutions. Its platform is used by global enterprises to manage vulnerabilities, ensure policy compliance, protect against threats, and inventory digital assets across hybrid environments. While we acknowledge the potential of QLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
SentinelOne (S) Expands Mimecast Partnership to Advance Human-Centric Cybersecurity
SentinelOne, Inc. (NYSE:S is one of the SentinelOne, Inc. (NYSE:S) is one of the best midcap AI stocks to buy right now. On August 6, 2025, SentinelOne announced an expanded partnership with Mimecast to advance human-centric cybersecurity. The integration connects SentinelOne's Singularity™ Platform with Mimecast's Human Risk Management (HRM) solution, enabling enterprises to correlate endpoint telemetry with behavioral insights and email-based threat intelligence. The goal is to strengthen real-time detection, automate risk scoring, and deliver targeted awareness training based on individual user behavior. Den Rise/ This collaboration marks a shift toward more adaptive, user-aware security frameworks. By analyzing how people interact with their environments, through devices, apps, and communications, the combined solution helps identify at-risk users and prioritize them for intervention. SentinelOne's AI-driven endpoint protection feeds into Mimecast's analytics to uncover patterns of risky behavior, enhancing both detection and prevention efforts. SentinelOne is a California-based cybersecurity company that provides autonomous endpoint protection, cloud security, and identity threat detection through its Singularity™ Platform. The company employs artificial intelligence and machine learning to deliver real-time threat prevention, detection, and response at machine speed. While we acknowledge the potential of S as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and .
